Company
-
Disney Trades Down ESPN Stake To Secure NFL Network & Redzone—Can It Surpass Netflix’s Live-Sports Ambitions?
Disney agreed to swap a 10 percent stake in ESPN for full control of NFL Network and RedZone—a deal worth…
Read More » -
Avantor Faces Activist Fire: Why Engine Capital Wants It Sold Now!
Avantor has landed in the sights of Engine Capital, which has built a 3% stake and is now pressing the…
Read More » -
Intel’s NEX Spin-Out Faces A Game-Changer—Ericsson Steps Up
Intel’s freshly spun-off networking and edge business, NEX, is making waves after reports surfaced that Ericsson is in late-stage talks…
Read More » -
Is Amphenol’s $10.5 Billion Commscope Play The Next AI Goldmine—Or A Risky Gamble?
Amphenol has reignited Wall Street chatter by edging toward a $10.5 billion deal for CommScope’s CCS broadband connectivity & cable…
Read More » -
HNI’s Bold $2.2 Billion Steelcase Gambit: A New Chapter In The Office Furniture Market?
HNI's announcement that it will acquire Steelcase in a $2.2 billion cash-and-stock deal has catalyzed intense debate among investors and…
Read More » -
Y-mAbs’ $412 Million Take-Private Offer From SERB Poised To Upset The Oncology Landscape
Y-mAbs Therapeutics stunned investors when SERB Pharmaceuticals announced an all-cash bid to take the company private at $8.60 per share,…
Read More » -
Palantir’s Pentagon Power Play: The Story Behind The $7.1 Billion Backlog & The 600% Rally!
As Palantir’s stock has climbed over 600% in the past year, its LTM EV/ Revenue multiple stands at 118x which…
Read More » -
ODP Is Exploring A Potential Sale: Why Private Equity Is Circling Fast!
According to a Dealreporter item dated July 29, 2025, ODP has engaged JPMorgan to assist with the sale process and…
Read More » -
Abbvie’s $1 Billion Gilgamesh Gambit: The Deal That Could Rewrite Its Future!
AbbVie’s recent confirmation that it’s in talks to acquire Gilgamesh Pharmaceuticals for roughly $1 billion underscores its unrelenting push to…
Read More » -
Axogen In Play? Here’s Why A Buyout Makes Sense At $18 Per Share
According to a report by StreetInsider, an unnamed strategic buyer has offered $18 per share for the company, prompting Axogen…
Read More »
